Multiple analytical platforms are used for measuring core CSF AD biomarkers, for example, INNOTEST (Fujirebio) provides clinically validated enzyme‐linked immunosorbent assays (ELISA) for Aβ42, total tau (t‐tau), and phosphorylated tau at site 181 (p‐tau181); the Meso Scale Discovery (MSD) Aβ triplex electrochemiluminescence assay simultaneously measures Aβ38, Aβ40, and Aβ42. The gene discussed is MAPT; the disease is Alzheimer disease.